Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events

NCT07607587 · Not yet recruiting

Last updated 2026-05-28

This clinical trial is testing the tolerability of the medication cagrilintide in adults with obesity or overweight who have not been able to tolerate GLP-1 receptor agonist therapies due to stomach-related side effects.

Status Not yet recruiting Approved but enrollment has not started.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 114 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2026-05 · est. completion 2027-11

Where 11 sites · United States

What this study is testing ClinicalTrials.gov NCT07607587 ↗

Description as written by the study sponsor.

The purpose of this clinical study is to look at the safety of the medicine Cagrilintide when compared to placebo in people who do not tolerate marketed glucagon-like peptide-1 (GLP-1) therapies and who live with overweight or obesity. Participants will get either Cagrilintide (the treatment being tested) or Placebo (a treatment that has no active medicine in it). Which treatment participant will get is decided by chance. The study will last for about 8 months.

Treatments tested

Cagrilintide Drug

Cagrilintide will be administered subcutaneously.
Placebo (matched to Cagrilintide) Drug

Placebo matched to Cagrilintide will be administered subcutaneously.

Main thing measured	Percentage of participants on standard dose or higher dose (yes/no) of cagrilintide and placebo
Sponsor	Novo Nordisk A/S
Conditions studied	Obesity, Overweight
GLP-1 drugs	cagrilintide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07607587 ↗